Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

McNeel, DG; Eickhoff, JC; Wargowski, E; Johnson, LE; Kyriakopoulos, CE; Emamekhoo, H; Lang, JM; Brennan, MJ; Liu, G

McNeel, DG (通讯作者)，Univ Wisconsin, Dept Med, Carbone Canc Ctr, Madison, WI 53706 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (3):

Abstract

Background We previously reported a trial using a DNA vaccine encoding prostatic acid phosphatase (MVI-816, pTVG-HP), given over 12 weeks concurrently......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索